• Policy
• Reimbursement application submitted for 'Adempas tab'
• by Lee, Tak-Sun Jul 10, 2024 05:48am

• Policy
• 1st bispecific antibody Epkinly approved with a condition
• by Lee, Hye-Kyung Jul 9, 2024 05:51am

• Policy
• BMS’ Camzyos and Handok’s Empaveli pass the DREC review
• by Lee, Tak-Sun Jul 9, 2024 05:51am

• Policy
• Reassessing the comparison of foreign drug pricing is 'idle'
• by Lee, Tak-Sun Jul 8, 2024 05:46am

• Policy
• 10th external reference pricing reeval meeting is held
• by Lee, Tak-Sun Jul 5, 2024 05:48am

• Policy
• Daewoong·Ildong late entries to the dapagliflozin market
• by Lee, Tak-Sun Jul 4, 2024 05:52am

• Policy
• GSK will discontinue supply of Infanrix IPV
• by Lee, Tak-Sun Jul 2, 2024 05:48am

• Policy
• Expenses for the major four severe diseases tops KRW 7T
• by Lee, Tak-Sun Jul 1, 2024 05:47am

• Policy
• Gov't releases generic drug price comparison study results
• by Lee, Tak-Sun Jun 27, 2024 05:47am

• Policy
• Some Akynzeo products recalled due to insufficient API
• by Lee, Hye-Kyung Jun 27, 2024 05:47am